Independent prospective study defines reference range for caredx's allosure for long-term lung transplant surveillance

Brisbane, calif.--( business wire )--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in transplantation direct1 which establishes a reference baseline when using allosure® lung in the long-term surveillance of lung transplant patients.
CDNA Ratings Summary
CDNA Quant Ranking